13F Holdings
中文EN

ADIA Adia Med, Inc.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1160420 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin35.3%
Operating margin-38.0%
Net margin-41.5%
FCF margin-27.2%
EBITDA margin-37.5%

Returns

ROE-111.0%
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets60.4%
Debt / equity0.00x
Current ratio1.09x
Interest coverage-20.10x

Cash quality & payout

Operating cash flow / net income0.62x
Accruals ratio—
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$700,508$6,380
Cost of revenue$508,838$4,186
Gross profit$191,670$2,194
R&D expense$29,144$0
SG&A expense$479,955$140,409
Operating income-$366,492-$174,749
Interest expense$31,597$6,318
Pretax income-$395,464-$181,067
Income tax$0$0
Net income-$395,464-$181,067
EBITDA-$362,350-$174,316
EPS (basic)0.000.00
EPS (diluted)0.000.00
Weighted avg. shares (diluted)93.60M91.74M
Balance sheet
Cash & equivalents$79,392$6,323
Receivables$33,360$0
Inventory$25,025$206,886
Current assets$161,510$258,393
PP&E, net$30,695$21,637
Intangibles$0$5,910
Total assets$594,826$666,181
Current liabilities$745,195$79,993
Total liabilities$852,500$640,641
Shareholders' equity-$257,674$25,540
Cash flow statement
Operating cash flow-$179,228-$335,476
Capital expenditure$13,200$21,831
Free cash flow-$192,428-$357,307
Investing cash flow-$32,051-$25,980
Financing cash flow$284,348$367,279
Depreciation & amortization$4,142$433
Stock-based compensation$42,250$30,857

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.